AIE‐Augmented NIR‐II‐Emissive Supramolecular Metallacycle Nanoplatform for Tumor Microenvironment‐Responsive Chemo‐Photothermal‐Immunotherapy
Advanced Healthcare Materials · 2026-01 · 15 (1)
DOI: 10.1002/adhm.202502963 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Healthcare Materials, online erschienen am 18.08.2025. Verfasst von Yaofeng Chen und 5 weiteren Autor:innen. Beteiligte Einrichtung: Key Laboratory of Organosilicon Chemistry and Materials Technology of the Ministry of Education, Zhejiang Key Laboratory of Organosilicon Material Te…. Hauptthemen laut MEDLINE: Tumor Microenvironment, Immunotherapy, Photothermal Therapy, Nanoparticles. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 63 Literaturangaben. Gefördert von: Interdisciplinary Research Project of Hangzhou Normal University, Natural Science Foundation of Zhejiang Province.
Abstract (Originalsprache)
The integration of multimodal therapies into a single nanoplatform promises significant advances in precision oncology, yet structural instability, premature drug leakage, and insufficient immune activation remain key challenges. Herein, a supramolecular metallacycle‐based nanoplatform ( M2S‐AD NPs) is engineered through coordination‐driven self‐assembly and β ‐cyclodextrin‐mediated host‐guest encapsulation. The metallacycle exhibits aggregation‐induced emission (AIE) characteristics to amplify NIR‐II fluorescence (1084 nm) for real‐time tumor imaging and achieves a record‐high photothermal conversion efficiency (42.7%) under 808 nm irradiation, enabling deep‐tissue photothermal ablation. Leveraging tumor microenvironment (TME)‐responsive disulfide bonds and pH‐labile Pt‐N coordination, M2S‐AD NPs selectively release chemotherapeutic agents in glutathione‐rich tumors while maintaining stability under physiological conditions. Synergistically, localized hyperthermia induces immunogenic cell death, releasing tumor antigens to prime dendritic cells, while co‐delivered anti‐PD‐L1 antibodies reverse immunosuppression, amplifying cytotoxic T lymphocyte infiltration. In 4T1 breast tumor models, this combinatorial strategy eradicates primary tumors and suppresses distant metastases with >80% tumor growth inhibition without inducing systemic toxicity. By unifying AIE‐enhanced imaging, TME‐triggered drug release, and immunomodulation, this work establishes a supramolecular engineering paradigm for next‐generation cancer theranostics, bridging material innovation with immunooncology to combat metastatic malignancies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Key Laboratory of Organosilicon Chemistry and Materials Technology of the Ministry of Education, Zhejiang Key Laboratory of Organosilicon Material Technology, College of Materials, Chemistry and Chemical Engineering, Ha…
ORCID-Profile: Shouchun Yin
Förderung
- Interdisciplinary Research Project of Hangzhou Normal University
- Natural Science Foundation of Zhejiang Province
Zitieren
APA
Chen, Y., Ma, W., Yu, Y., Niu, Q., Li, Y., & Yin, S. (2026). AIE‐Augmented NIR‐II‐Emissive Supramolecular Metallacycle Nanoplatform for Tumor Microenvironment‐Responsive Chemo‐Photothermal‐Immunotherapy. Advanced Healthcare Materials, 15(1). https://doi.org/10.1002/adhm.202502963
Vancouver
Chen Y, Ma W, Yu Y, Niu Q, Li Y, Yin S. AIE‐Augmented NIR‐II‐Emissive Supramolecular Metallacycle Nanoplatform for Tumor Microenvironment‐Responsive Chemo‐Photothermal‐Immunotherapy. Advanced Healthcare Materials. 2026;15(1). doi:10.1002/adhm.202502963
BibTeX
@article{Chen2026,
author = {Chen, Yaofeng and Ma, Wei and Yu, Yanlu and Niu, Qian and Li, Yang and Yin, Shouchun},
title = {AIE‐Augmented NIR‐II‐Emissive Supramolecular Metallacycle Nanoplatform for Tumor Microenvironment‐Responsive Chemo‐Photothermal‐Immunotherapy},
journal = {Advanced Healthcare Materials},
year = {2026},
volume = {15},
number = {1},
doi = {10.1002/adhm.202502963}
}
EUVIMED